Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 100000
Summary
- Conditions
- Cancer
- Cardiac Disease
- Type
- Observational
- Design
- Observational Model: Case-OnlyTime Perspective: Cross-Sectional
Participation Requirements
- Age
- Younger than 100 years
- Gender
- Both males and females
Description
Antineoplastic therapies are responsible of a wide range of cardio-vascular side effects.The investigators use VigiBase, the World Health Organization (WHO) database of individual safety case reports, to identify cases of cardiovascular adverse drug reactions following treatment with antineoplastic ...
Antineoplastic therapies are responsible of a wide range of cardio-vascular side effects.The investigators use VigiBase, the World Health Organization (WHO) database of individual safety case reports, to identify cases of cardiovascular adverse drug reactions following treatment with antineoplastic and immunomodulating agents
Tracking Information
- NCT #
- NCT03530215
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon